JMP Securities Reiterates "Market Outperform" Rating for Savara (NASDAQ:SVRA)

Savara (NASDAQ:SVRA - Get Free Report)'s stock had its "market outperform" rating restated by equities research analysts at JMP Securities in a note issued to investors on Monday, Benzinga reports. They currently have a $8.00 target price on the stock. JMP Securities' target price points to a potential upside of 61.62% from the company's current price.

Separately, Piper Sandler boosted their price target on Savara from $7.00 to $16.00 and gave the company an "overweight" rating in a report on Monday, March 4th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Savara has an average rating of "Buy" and an average price target of $8.20.

Savara Stock Performance

Shares of SVRA stock traded up $0.25 during trading hours on Monday, hitting $4.95. The company's stock had a trading volume of 878,649 shares, compared to its average volume of 864,806. The stock has a market cap of $683.99 million, a PE ratio of -15.00 and a beta of 0.73. Savara has a 12-month low of $1.83 and a 12-month high of $5.70. The company has a 50 day moving average of $4.90 and a 200 day moving average of $4.50. The company has a current ratio of 15.66, a quick ratio of 15.66 and a debt-to-equity ratio of 0.19.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. On average, sell-side analysts forecast that Savara will post -0.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Savara

Large investors have recently bought and sold shares of the business. Jennison Associates LLC increased its position in shares of Savara by 128.0% in the fourth quarter. Jennison Associates LLC now owns 8,815,358 shares of the company's stock valued at $41,432,000 after buying an additional 4,948,596 shares in the last quarter. Wellington Management Group LLP acquired a new position in Savara during the fourth quarter worth $9,683,000. Vivo Capital LLC purchased a new position in Savara during the third quarter valued at $7,232,000. Adage Capital Partners GP L.L.C. grew its position in shares of Savara by 30.9% in the third quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company's stock valued at $30,008,000 after purchasing an additional 1,874,000 shares during the period. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of Savara during the third quarter worth about $4,347,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.